Table 4.

Repeated measures logistic regression of cardiovascular risk scores with frailty in WIHS women ^a,b,c

	HIV− (n=1,718 study visits, 185 frail visits)			HIV+ (n=4,546 study visits, 494 frail visits)
	OR	95% CI	P ^a	OR	95% CI	P ^a
Cardiovascular risk scores, continuous
ATP-III FRS, % (unadjusted)	1.06	1.02, 1.10	0.003	1.05	1.02, 1.08	<0.001
ATP-III FRS, % (adjusted)	1.02	0.98, 1.07	0.32	1.04	1.01, 1.07	0.009
ACC/AHA PCE, % (unadjusted)	1.03	1.02, 1.04	<0.001	1.02	1.01, 1.03	<0.001
ACC/AHA PCE, % (adjusted)	1.02	1.00, 1.03	0.01	1.01	1.00, 1.02	0.07
Cardiovascular risk scores, strata
ATP-III FRS, %
Low risk (<10%)	Ref			Ref
Moderate risk (10–20%) (unadjusted)	1.19	0.46, 3.05	0.72	1.23	0.76, 2.00	0.40
Moderate risk (10–20%) (adjusted)	0.83	0.33, 2.09	0.69	1.11	0.68, 1.81	0.67
High risk (>20%) (unadjusted)	1.65	0.48, 5.62	0.42	0.78	0.19, 3.24	0.73
High risk (>20%)(adjusted)	1.03	0.30, 3.49	0.96	0.86	0.23, 3.20	0.82
ACC/AHA PCE, %
Low risk (<7.5%)	Ref			Ref
High risk (≥7.5%) (unadjusted)	1.77	1.29, 2.43	<0.001	1.52	1.22, 1.90	<0.001
High risk (≥7.5%) (adjusted)	1.43	1.02, 2.00	0. 04	1.36	1.08, 1.71	0.01

ACC/AHA PCE: American College of Cardiology/American Heart Association pooled cohort equations; ATP-III FRS: Adult Treatment Program III Framingham risk score; CI: confidence interval; HIV: human immunodeficiency virus; OR: odds ratio; WIHS: Women’s Interagency HIV Study

Adjusted analyses include as covariates: education, income, cholesterol medication use, HCV serostatus, and in HIV+ participants, CD4 count, ART therapy and suppressed HIV viral load

ATP-III FRS and ACC/AHA PCE are in women 20–79 and 40–79 years of age, respectively

ACC/AHA PCE were available for 1,432 (83%) HIV− and 4,029 (89%) HIV+ study visits